Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.32 |
| ▸ | CRHBP | P24387 | 1/20 | 0.32 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4603698 | 0.81 | CA2 (0.70) | CA2CA1 | |
| SCHEMBL4604622 | 0.77 | CA2 (0.62) | CA2ALDH1A1CA1CHRNA7CRHBP | |
| SCHEMBL4272983 | 0.70 | CA2 (0.36) | CA2 | |
| SCHEMBL4276579 | 0.64 | CA2 (1.00) | CA2ALDH1A1CA1HPGD | |
| SCHEMBL13080543 | 0.64 | CA1 (0.53) | CA2CA1CHRNA7CRHBPCRHR2 | |
| SCHEMBL2452519 | 0.62 | ALDH1A1 (0.61) | CA2ALDH1A1CA1KDM4EHPGD | |
| SCHEMBL4605121 | 0.61 | CYP2A6 (0.47) | CA2CA1LMNAMEN1KMT2A | |
| SCHEMBL1014809 | 0.59 | PKM (0.67) | ALDH1A1SMN1; SMN2KDM4EMEN1KMT2A | |
| SCHEMBL4273045 | 0.59 | CA2 (0.66) | CA2CA1 | |
| SCHEMBL14362536 | 0.58 | TSHR (0.68) | ALDH1A1SMN1; SMN2KDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090176996-A1 | PROCESS FOR THE PREPARATION OF SULFAMIDE DERIVATIVES | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176996-A1 | PROCESS FOR THE PREPARATION OF SULFAMIDE DERIVATIVES | STS, SULT2A1, SULT1A1 | CA2 1316/4885ALDH1A1 550/4885CA1 449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.